InnovationNew Jersey
  • Home
  • Our Coalition
    • Who We Are
    • Contact Us
  • News
  • Events
  • Join Us
  • Resources
    • Mapping NJ Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
    • Industry Supports

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Rutgers and Dartmouth Researchers: Pursuing the Destruction of HIV-infected Cells

6/6/2016

0 Comments

 
New Brunswick, NJ ― Dory Devlin at Rutgers University reports that an oral drug used to treat an illness unrelated to HIV eradicated infectious HIV-producing cells in lab cultures while sparing uninfected cells — and suppressed the virus in patients during treatment and for at least eight weeks after the drug was stopped, according to results of a clinical pilot trial and researchers at Rutgers University and Dartmouth College.
 
The findings, published May 18 in the scientific journal PLOS ONE, point to development of a promising HIV treatment that could destroy the HIV DNA harbored in HIV-infected cells.  Current HIV-AIDS treatments center on antiretroviral drugs that, when taken in combination for all of a patient’s life, can prevent the growth of the virus but not kill or cure it.
 
“For the first time, we show that it’s possible with a systemic drug to selectively kill the AIDS-causing HIV-infected cells,” said Hartmut Hanauske-Abel, a researcher from Rutgers New Jersey Medical School, a lead author of the study with appointments in the departments of Obstetrics, Gynecology and Women’s Health; Pediatrics; and Microbiology, Biochemistry and Molecular Genetics.
 
Treatment that targets the DNA in HIV-infected cells has been challenging because the persistent, incurable human immunodeficiency virus is able to insert its own DNA into the DNA of any infected cell while disabling that cell’s ability to die to save other cells from a viral invasion. 
​The researchers found that the oral drug, deferiprone, like the topical anti-fungal medicine ciclopirox that they previously studied, reactivates the “altruistic suicide response” of an HIV-infected cell, killing the HIV DNA it carries.
 
The clinical pilot trial — conducted by the Toronto-based firm, ApoPharma Inc., which markets deferiprone — involved 26 consenting volunteers, both HIV-infected and healthy.  Some participants received placebos, others the drug at two different doses.
 
Analyzing the raw data, the researchers found that of seven participants with HIV whose serum registered a necessary threshold concentration of the drug while taking it during the seven-day protocol, six showed positive HIV responses while in treatment.  Participants who completed the entire protocol maintained their responses after drug treatment was stopped for eight weeks.
 
The authors cautioned that the findings do not prove that deferiprone in its current form is a safe and effective treatment for HIV.
 
But the findings do provide researchers with ample evidence to pursue funding for larger clinical trials and to use the drug as a lead for future drug development, they said.
 
The main function of this proof-of-concept trial was to learn that it is possible to have a drug that knocks down HIV and prevents its rebound.
 
“The discovery raises the hope that HIV may not be able to develop resistance against this novel class of drugs,” said study co-author Paul Palumbo of Dartmouth’s Geisel School of Medicine. “It gives credence to the concept that like cancer cells, HIV-infected cells can be targeted and eliminated by a drug.”
 
Resistance commonly develops when treating HIV with widely used antiretrovirals. Despite the short, seven-day trial, deferiprone’s effect on reducing HIV blood levels was similar to a multi-week treatment with AZT, zidovudine, an antiretroviral commonly used to treat HIV. The anti-HIV effect of deferiprone persisted after the drug was stopped — “an effect quite different from all current antiretrovirals,” the researchers said.
 
Regulatory guidelines for developing new antiviral drugs for HIV focus on inhibiting viral production and avoid using agents that kill cells that are actively or latently HIV-infected.
 
That’s why this group of researchers is focused on developing protocols for already approved drugs used for other medical treatments that show promise in eradicating HIV-infected cells, and on testing new combinations of those drugs for novel treatment protocols.
 
Deferiprone, available for the past 20 years, is used in more than 60 countries to prevent death from blood transfusion-related complications during treatment of thalassemia, an inherited blood disorder in which the body makes an abnormal form of hemoglobin.
 
The HIV-AIDS pandemic persists. Worldwide, 36.9 million people live with HIV-1, yet only 14.9 million (40 percent) are treated. The study also notes increases in HIV-1 infections in several U.S. cities in the U.S. and worldwide. At the end of 2012, an estimated 1.2 million people aged 13 and older were living with HIV infection in the United States, including 156,300 (12.8 percent) whose infections were not diagnosed, according to the Centers for Disease Control.
 
The study published in PLOS ONE is the result of a 15-year research effort by the joint senior authors, Dartmouth's Palumbo of Dartmouth and Rutgers' Hanauske-Abel . They integrated university-, government-, and industry-based researchers from the United States and Canada in a combined effort to define the testable prospects of this novel treatment strategy for HIV-AIDS.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Powered by Create your own unique website with customizable templates.